Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 1
2007 6
2008 1
2009 3
2010 3
2011 4
2012 2
2013 3
2014 4
2015 5
2016 5
2017 3
2018 6
2019 2
2020 4
2021 4
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Rizvi NA, et al. Among authors: moiseyenko v. JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237. JAMA Oncol. 2020. PMID: 32271377 Free PMC article. Clinical Trial.
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
de Castro G Jr, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, Lee SY, Bryl M, Zer A, Erman M, Timcheva C, Raja R, Naicker K, Scheuring U, Walker J, Mann H, Chand V, Mok T; NEPTUNE Investigators. de Castro G Jr, et al. Among authors: moiseyenko v. J Thorac Oncol. 2023 Jan;18(1):106-119. doi: 10.1016/j.jtho.2022.09.223. Epub 2022 Oct 12. J Thorac Oncol. 2023. PMID: 36240972 Free article. Clinical Trial.
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Van Cutsem E, et al. Among authors: moiseyenko v. J Clin Oncol. 2012 Oct 1;30(28):3499-506. doi: 10.1200/JCO.2012.42.8201. Epub 2012 Sep 4. J Clin Oncol. 2012. PMID: 22949147 Clinical Trial.
Tumor acidity: From hallmark of cancer to target of treatment.
Bogdanov A, Bogdanov A, Chubenko V, Volkov N, Moiseenko F, Moiseyenko V. Bogdanov A, et al. Among authors: moiseyenko v. Front Oncol. 2022 Aug 29;12:979154. doi: 10.3389/fonc.2022.979154. eCollection 2022. Front Oncol. 2022. PMID: 36106097 Free PMC article. Review.
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. Morgan G, et al. Among authors: moiseyenko v. ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. ESMO Open. 2016. PMID: 28255451 Free PMC article. Review.
Cell technologies in immunotherapy of cancer.
Moiseyenko V, Imyanitov E, Danilova A, Danilov A, Baldueva I. Moiseyenko V, et al. Adv Exp Med Biol. 2007;601:387-93. doi: 10.1007/978-0-387-72005-0_42. Adv Exp Med Biol. 2007. PMID: 17713028 Review.
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I. Tjulandin S, et al. Among authors: moiseyenko v. Eur J Cancer. 2021 May;149:222-232. doi: 10.1016/j.ejca.2021.02.030. Epub 2021 Apr 17. Eur J Cancer. 2021. PMID: 33872982 Free article. Clinical Trial.
Drug therapy for hereditary cancers.
Imyanitov EN, Moiseyenko VM. Imyanitov EN, et al. Among authors: moiseyenko vm. Hered Cancer Clin Pract. 2011 Aug 6;9(1):5. doi: 10.1186/1897-4287-9-5. Hered Cancer Clin Pract. 2011. PMID: 21819606 Free PMC article.
59 results